EUVIMEDEUVIMED entdecken
Fallbericht

Meningioma regression following discontinuation of depot medroxyprogesterone acetate

Alan Gordillo, Pranav Kumar, Nikita Gonugunta, Alejandro Torres-Trejo, Pranay Soni, Pablo F Recinos, Varun R Kshettry

Neurosurgical Focus · 01.09.2026 · 61 (3) · E3

DOI: 10.3171/2026.6.focus26225 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neurosurgical Focus, erschienen am 01.09.2026. Verfasst von Alan Gordillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine, Cleveland. Hauptthemen laut MEDLINE: Meningioma, Medroxyprogesterone Acetate, Meningeal Neoplasms, Contraceptive Agents, Female. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The aim of this study was to assess the clinical and radiographic changes in meningioma burden following cessation of depo-medroxyprogesterone acetate (dMPA) in patients with meningioma stabilization or shrinkage. METHODS This retrospective case series included 3 patients with meningioma who did not undergo resection at the author’s institution but who discontinued dMPA during tumor surveillance (2020–2025) and experienced tumor regression. Data collection included meningioma characteristics, previous pathology reports, tumor size across various follow-up time points, and clinical course. RESULTS The mean cumulative duration of dMPA was 19.7 ± 2.5 years. Tumor regression was identified as early as 14 months after cessation of dMPA and persisted beyond 68 months after cessation. Patient A, with ≥ 20 tumors, demonstrated nearly 39% reduction in overall tumor burden across 45 months. Patient B demonstrated nearly 80% decrease in tumor burden across 68 months. Patient C demonstrated a 6% decrease in tumor burden, with near-complete resolution of 1 anterior skull-base tumor, within 14 months of dMPA cessation. CONCLUSIONS The authors present 3 patients with previously diagnosed meningioma who were managed with active surveillance and dMPA cessation. After 12 months of follow-up, all patients demonstrated decreases in overall tumor burden. These results highlight an evolving understanding in the management of patients with possible progestin-associated meningioma in the setting of dMPA exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMedroxyprogesterone AcetateMeningeal NeoplasmsContraceptive Agents, FemaleContraceptive Agents, HormonalHumansFemaleRetrospective StudiesMiddle AgedAdult

Stichwörter der Autor:innen

medroxyprogesterone acetateprogestin-associated meningiomastumor

Substanzen

Medroxyprogesterone AcetateContraceptive Agents, FemaleContraceptive Agents, Hormonal

Autor:innen und Institutionen

  • 1Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine, Cleveland.
  • 2Case Western Reserve University School of Medicine, Cleveland; and.
  • 3Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.

Zitieren

APA

Gordillo, A., Kumar, P., Gonugunta, N., Torres-Trejo, A., Soni, P., Recinos, P. F., & Kshettry, V. R. (2026). Meningioma regression following discontinuation of depot medroxyprogesterone acetate. Neurosurgical Focus, 61(3), E3. https://doi.org/10.3171/2026.6.focus26225

Vancouver

Gordillo A, Kumar P, Gonugunta N, Torres-Trejo A, Soni P, Recinos PF, et al. Meningioma regression following discontinuation of depot medroxyprogesterone acetate. Neurosurgical Focus. 2026;61(3):E3. doi:10.3171/2026.6.focus26225

BibTeX
@article{Gordillo2026,
  author = {Gordillo, Alan and Kumar, Pranav and Gonugunta, Nikita and Torres-Trejo, Alejandro and Soni, Pranay and Recinos, Pablo F and Kshettry, Varun R},
  title = {Meningioma regression following discontinuation of depot medroxyprogesterone acetate},
  journal = {Neurosurgical Focus},
  year = {2026},
  volume = {61},
  number = {3},
  pages = {E3},
  doi = {10.3171/2026.6.focus26225}
}
Kostenlos starten →